The underlying assumption is that by lowering chemerin levels through dietary interventions, novel therapeutic strategies may be identified for the prevention and treatment of various cardiovascular diseases associated with obesity and metabolic syndrome. This evidence concerns the gene RARRES2 and obesity due to melanocortin 4 receptor deficiency.